Collegium Pharma (COLL): Cutting PT On Expenses But 1Q Could Be An Inflection - Jefferies

November 11, 2016 7:23 AM EST
Get Alerts COLL Hot Sheet
Price: $16.39 --0%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 15 | New: 18
Trade COLL Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Collegium Pharmaceutical (NASDAQ: COLL) but cut his price target to $24 from $27 after higher than expected SG&A spending led to a modestly higher loss.

That said, the company now has sufficient cash for operations into 2019 following a recent $80M financing. The analyst thinks that based on progress in the commercial launch and recent formulary wins, Xtampza Rxs are positioned for an inflection in 1H17 which could be meaningful to results since the analyst is projecting it to be a $400M+ peak product.

For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.

Shares of Collegium Pharmaceutical closed at $16.84 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Earnings

Related Entities

Jefferies & Co

Add Your Comment